EICHOR
● Active Not Recruiting
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Condition: Plaque Psoriasis · Sponsor: Janssen Research & Development, LLC
About this study
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (160)
| Cahaba Research Inc | Birmingham, Alabama, United States | — |
| California Dermatology & Clinical Research Institute | Encinitas, California, United States | — |
| T Joseph Raoof Md Inc | Encino, California, United States | — |
| First OC Dermatology | Fountain Valley, California, United States | — |
| Dermatologist Medical Group of North County, Inc. | Oceanside, California, United States | — |
| NorCal Clinical Research | Rocklin, California, United States | — |
| Integrative Skin Science and Research | Sacramento, California, United States | — |
| MedDerm Associates | San Diego, California, United States | — |
| Southern California Dermatology | Santa Ana, California, United States | — |
| Olive View-UCLA Education & Research Institute | Sylmar, California, United States | — |
| University of Conn Health Center | Farmington, Connecticut, United States | — |
| Driven Research LLC | Miami, Florida, United States | — |
+ 148 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.